Currently out of the existing stock ratings of Joseph Schwartz, 39 are a HOLD (15.73%), 203 are a BUY (81.85%), 6 are a SELL (2.42%).

Joseph Schwartz

Work Performance Price Targets & Ratings Chart

Analyst Joseph Schwartz, currently employed at LEERINK, carries an average stock price target met ratio of 60.27% that have a potential upside of 56.12% achieved within 351 days.

Joseph Schwartz’s has documented 510 price targets and ratings displayed on 47 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on KALV, Kalvista Pharmaceuticals at 07-Jul-2025.

Wall Street Analyst Joseph Schwartz

Analyst best performing recommendations are on LRMR (LARIMAR THERAPEUTICS).
The best stock recommendation documented was for LRMR (LARIMAR THERAPEUTICS) at 12/1/2015. The price target of $132 was fulfilled within 1 day with a profit of $59.16 (30.95%) receiving and performance score of 309.48.

Average potential price target upside

of $107.56 (69.09%) on ZFGN (ZAFGEN).
of $98.1 (51.05%) on SLDB (SOLID BIOSCIENCES LLC).
of $88.47 (17.01%) on REGN (REGENERON PHARMACEUTICALS).

AMAG AMAG Pharmaceuticals ARNA Arena Pharmaceuticals ASND Ascendis Pharma AS AUPH Aurinia Pharmaceuticals BMRN Biomarin Pharmaceutical CCXI ChemoCentryx FOLD Amicus Therapeutics ICPT Intercept Pharmaceuticals MDCO The Medicines Company PTGX Protagonist Therapeutics QURE Uniqure NV RARE Ultragenyx SLDB Solid Biosciences LLC SPRB Spruce Biosciences SRPT Sarepta Therapeutics AMTI Applied Molecular Transport BIIB Biogen CBAY Cymabay Therapeu ACHN Achillion Pharmaceuticals EWTX Edgewise Therapeutics GOSS Gossamer Bio IFRX InflaRx N.V. IMRA Imara INSM Insmed ONCE Spark Therapeutics RETA Reata Pharmaceuticals RPHM Reneo Pharmaceuticals BOLD Audentes Therapeutics DSGN Design Therapeutics PHVS Pharvaris BV RNA Avidity Biosciences TVTX Travere Therapeutics UTHR United Therapeutics ZFGN Zafgen KALV Kalvista Pharmaceuticals REGN Regeneron Pharmaceuticals SYBX Synlogic ALDR Alder BioPharmaceuticals CRNX Crinetics Pharmaceuticals KDNY Chinook Therapeutics PTI Proteostasis Therapeutics RTRX Travere Therapeutics ANTX AN2 Therapeutics LRMR Larimar Therapeutics FULC Fulcrum Therapeutics MREO Mereo BioPharma Group PLC ADR RGLS Regulus Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Christopher Raymond (PIPER SANDLER)